"Strengthening Global Partnerships"...ST Pharm Participates Simultaneously in TIDES USA and ASGCT in the US

ST Pharm announced on May 14 that it participated simultaneously in 'TIDES USA 2026' and 'ASGCT 2026 (American Society of Gene & Cell Therapy),' both held from May 11 to 14 (local time) at the Hynes Convention Center in Boston, USA.

ST Pharm Participates in 'TIDES USA 2026' and 'ASGCT 2026' Simultaneously. ST Pharm

TIDES USA is a global professional event that covers research and development (R&D), manufacturing (CMC), and regulatory strategies in the fields of oligonucleotides, peptides, mRNA, and gene editing. It is regarded as one of the world's largest industry forums, attracting major companies and key decision-makers in the nucleic acid therapeutics sector.

At TIDES USA, ST Pharm held a presentation session for global clients to showcase its contract development and manufacturing organization (CDMO) capabilities. According to the company, it not only emphasized the expansion of its production capacity but also shared its development and manufacturing strategies to address the next-generation nucleic acid therapeutics market.

During the event, ST Pharm also operated a booth introducing its CDMO expertise in the nucleic acid therapeutics field, including ▲siRNA ▲ASO ▲AOCs ▲guide RNA ▲Aptamer ▲mRNA-LNP. Based on its full-cycle development and manufacturing services, from preclinical and early clinical stages to commercial-scale production, the company held business meetings aimed at expanding new project orders and strengthening partnerships.

ST Pharm also dispatched key personnel to ASGCT 2026 during the same period. The company sought to identify the latest technology trends in the gene and cell therapy sector and promoted its LNP and next-generation nucleic acid therapeutic platform technologies to global pharmaceutical and biotech companies.

A representative from ST Pharm said, "We implemented a two-track networking strategy during the period when the global key events, TIDES USA and ASGCT, were held concurrently. Through this simultaneous participation, we plan to strengthen the foundation for strategic cooperation with global clients and accelerate the expansion of our mid- to long-term order pipeline."

Meanwhile, ST Pharm is expanding its competitiveness in the global nucleic acid therapeutics market based on its oligonucleotide active pharmaceutical ingredient (API) production capabilities, process development, analytical development, and cGMP-based commercial manufacturing systems. Leveraging its extensive experience in a variety of global projects, ST Pharm plans to continue discussions for collaboration with diverse clients.

This content was produced with the assistance of AI translation services.